Pear Bio analyzes patient tumor samples and data with a proprietary computational biology platform to deconvolute complex cancer biology and drive patient-centric functional precision medicine and drug discovery.

Pear Bio

Pear Bio analyzes patient tumor samples and data with a proprietary computational biology platform to deconvolute complex cancer biology and drive patient-centric functional precision medicine and drug discovery.

Our ultimate goal is to optimally allocate approved treatments to cancer patients who will benefit from them, while creating novel therapies that are purpose-designed for patients who don't respond to available treatments.

The platform uses microphysiological systems and 3D computer vision to measure cancer progression over time. Pear Bio cultures patient tumor samples with matched blood into 3D immune-microtumors to test potential treatment options and combinations ex vivo. A proprietary computer vision/DL pipeline finds image-based spatial biomarkers in time-course 3D microscopy data of patient 3D immune-microtumors. Each treatment option is compared using these image biomarkers to predict which treatments have high potential efficacy for each patient. 

Patient data and excess tissue/blood feed into a multi-omics pipeline, which allows us to find novel druggable targets in patients who don't respond to approved therapies. These targets are then developed into our in-house drug discovery pipeline, which eventually feeds back into clinical care through our predictive biomarker platform.


SOSV

RebelBio

Greater London Authority

Hoxton Ventures

Fly Ventures

Wavemaker 360

Octopus Ventures

Compound

Crista Galli Ventures

Our Winter 2023 newsletter now out, with a focus on our clinical trial work

https://lnkd.in/ewiz_XVw

Let us know if you have questions, or want to know more about our clinical trials!

The Pear Bio team is excited to have set up our first US lab in the Boston area at ABI-LAB 2 this month! The facilities and support provided by the team are second to none 🇺🇸  🇺🇸  🇺🇸 

This lab will focus on US clinical trials & lab developed testing.

We are looking forward to this new chapter for the company!

Really delighted that we have support from a range of charities for our trials.

Pear-Tree2 in kidney cancer from Kidney Cancer UK
Pear-TNBC in Triple Negative Breast Cancer from Breast Cancer Now

and both are open across a range of hospitals

https://lnkd.in/d5iYhvgV
https://lnkd.in/dYrU_EiZ

To read more about our trials, see here: https://lnkd.in/dvJkA5CN

msh id	COM:PEARBIO
symbol	-
name	Pear Bio
homepage url	https://pearbio.com
country	GB
sector	Healthcare
industry	Biotechnology Research
market	PRIVATE
employee count	34
crunchbase url	https://www.crunchbase.com/organization/pear-diagnostics
linkedin url	https://www.linkedin.com/company/pear-bio
founders	-

market cap	-
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	1.77
growth score 28	2.2
growth score 90	2.38
growth score 365	3.47

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-
growth cost of revenue	-
growth depreciation and amortization	-
growth ebitda	-
growth ebitda ratio	-
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	-
growth gross profit ratio	-

COM:PEARBIO

Pear Bio

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	-
cost of revenue	-
depreciation and amortization	-
ebitda	-
ebitda ratio	-
eps	-
eps diluted	-
operating expenses	-
operating income	-
operating income ratio	-

accounts receivables	-
capital expenditure	-
cash at beginning of period	-
cash at end of period	-
inventory	-
working capital ttm	-

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-